TFX Teleflex Incorporated

Teleflex Announces Planned Retirement of Thomas Powell As Chief Financial Officer

Teleflex Announces Planned Retirement of Thomas Powell As Chief Financial Officer

John Deren To Be Named Executive Vice President and Chief Financial Officer

WAYNE, Pa., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX), a leading global provider of medical technologies, today announced that Thomas E. Powell, Teleflex’s Chief Financial Officer, has decided to retire as Executive Vice President and Chief Financial Officer, effective April 1, 2025. John R. Deren, who currently serves as Corporate Vice President and Chief Accounting Officer of Teleflex, will succeed Mr. Powell as Executive Vice President and Chief Financial Officer, effective April 2, 2025. Following his retirement, Mr. Powell will serve as a consultant to the company through March 31, 2026 to support continuity and a smooth transition.

“Tom has announced his desire to retire from Teleflex after more than 13 years with the company,” said Liam Kelly, Chairman, President and Chief Executive Officer of Teleflex. “Over the years, Tom has been a trusted partner in our efforts to build a durable growth company. He has been instrumental in driving adjusted operating margin expansion, which increased 800 bps from 2012-2024. As the company has grown, Tom has built a highly capable global finance organization, which keeps us well-positioned for the future. I would also like to recognize Tom’s prioritization to his own succession planning to ensure a well-planned and smooth transition in finance leadership. I want to thank Tom for his numerous contributions to Teleflex and congratulate him on his upcoming retirement. I also want to welcome John as the new chief financial officer and look forward to working closely with him. John’s knowledge of the Teleflex business and his trusted stewardship of the finance function will provide continuity and be instrumental as we continue to execute our growth strategy.”

Mr. Deren has had a wide-ranging set of responsibilities within the Teleflex Finance organization since joining the company in 2013. During his tenure, John has had executive oversight of various functions within Finance, including Corporate Finance, Finance Shared Services, Global Supply Chain Finance, Treasury, and Tax.

John has over 30 years of financial management and reporting experience for public companies. He began his career and obtained his CPA at PricewaterhouseCoopers and progressed to then hold finance leadership roles at Rohm and Haas, Exelon Generation, and Trinseo prior to joining Teleflex.

About Teleflex Incorporated

As a global provider of medical technologies, Teleflex is driven by our purpose to improve the health and quality of people’s lives. Through our vision to become the most trusted partner in healthcare, we offer a diverse portfolio with solutions in the therapy areas of anesthesia, emergency medicine, interventional cardiology and radiology, surgical, vascular access, and urology. We believe that the potential of great people, purpose driven innovation, and world-class products can shape the future direction of healthcare.

Teleflex is the home of Arrow™, Barrigel™, Deknatel™, LMA™, Pilling™, QuikClot™, Rüsch™, UroLift™ and Weck™ – trusted brands united by a common sense of purpose.

At Teleflex, we are empowering the future of healthcare. For more information, please visit .

Forward-Looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Any forward-looking statements contained herein are based on our management's current beliefs and expectations, but are subject to a number of risks, uncertainties and changes in circumstances, which may cause actual results or company actions to differ materially from what is expressed or implied by these statements. These risks and uncertainties are identified and described in more detail in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K.

Teleflex, the Teleflex logo, Arrow, Barrigel, Deknatel, LMA, Pilling, QuikClot, Titan SGS, Rüsch, UroLift and Weck are trademarks or registered trademarks of Teleflex Incorporated or its affiliates, in the U.S. and/or other countries. © 2025 Teleflex Incorporated. All rights reserved.

Contacts:

Teleflex

Lawrence Keusch

Vice President, Investor Relations and Strategy Development

610-948-2836



EN
27/02/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Teleflex Incorporated

 PRESS RELEASE

First Patient Enrolled in DUBSTENT DIABETES Trial: Targeting Improved ...

First Patient Enrolled in DUBSTENT DIABETES Trial: Targeting Improved PCI Outcomes for Diabetic Patients The Trial Evaluates a Combined PCI Approach Using Drug-Coated Balloons and Drug-Eluting Stents WAYNE, Pa., Sept. 11, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX), a leading global provider of medical technologies, today announced the enrollment of the first patient in the DUBSTENT DIABETES trial. The randomized, investigator-initiated clinical study will evaluate a dual-device strategy for percutaneous coronary intervention (PCI) in patients with diabetes mellitus. The ...

 PRESS RELEASE

Teleflex to Present at the Morgan Stanley 23rd Annual Global Healthcar...

Teleflex to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference WAYNE, Pa., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Management of Teleflex Incorporated (NYSE: TFX) will be presenting at the Morgan Stanley 23rd Annual Global Healthcare Conference at the Sheraton New York Times Square, on Tuesday, September 9, 2025, at 3:20 p.m. (ET). A live audio webcast of the conference presentation will be available on the investor section of the Teleflex website at . About Teleflex IncorporatedAs a global provider of medical technologies, Teleflex is driven by our purpose to improve the ...

 PRESS RELEASE

Teleflex Announces the Launch of Barrigel™ Rectal Spacer in Japan as a...

Teleflex Announces the Launch of Barrigel™ Rectal Spacer in Japan as a Proven Safe and Effective Option to Minimize the Harmful Long-Term Side Effects of Prostate Radiation Therapy Innovative hyaluronic acid technology delivers enhanced control and precision, significantly lowering the risk of rectal toxicity during prostate radiation treatment.1-4Initial cases have now been performed in Japan. WAYNE, Pa., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced Barrigel™ rectal spacer is now available for pur...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: August 9, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Teleflex Inc: 5 directors

Five Directors at Teleflex Inc bought 5,500 shares at between 114.750USD and 115.860USD. The significance rating of the trade was 66/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch